epilepsy
Conditions
Interventions
Lacosamide group:Nil
control group:Nil
Sponsors
Children's Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 16 Years
Inclusion criteria
Inclusion criteria: 1. Aged =1 in the three months before screening; 4. Informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1. The subject has a known allergy to any component of the study drug; 2. Patients whose epileptic seizure frequency cannot be determined in the first three months of enrollment; 3. The subject has taken LCM or participated in a clinical trial of LCM, and was terminated due to lack of efficacy or adverse events; 4. The subject is receiving ketogenic diet therapy; 5. The subject suffers from congenital heart disease, cardiac sodium channel disease, and arrhythmic heart disease that have a significant impact on hemodynamics; 6. The upper limit of normal value (ULN) of the following substances in the subject is> 2 times: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) or total gallbladder Red pigment>upper limit of normal value (if Gilbert syndrome is known, total bilirubin>1.5 times the upper limit of normal value); 7. Subject's creatinine > 445umol/L; 8. The researcher believes that the subject is not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seizure frequency; | — |
Countries
China
Contacts
Public ContactXiao Nong
Children's Hospital of Chongqing Medical University
Outcome results
None listed